Etomoxir (Standaard)

Etomoxir (Standard) is the analytical standard of Etomoxir. This product is intended for research and analytical applications. Etomoxir ((R) - (+) -Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.

124083-20-1

12352100

Apoptosis; Reference Standards

Apoptosis; Others

Cancer; Metabolic Disease

O=C(OCC)[C@@]1(OC1)CCCCCCOC2=CC=C(C=C2)Cl

C17H23ClO4

326.82

[1]Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27 (7) :621-36.|[2]Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.
 J Lipid Res. 2003 Feb;44 (2) :415-23.|[3]Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724.|[4]Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419 (2) :447-55.|[5]O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8 (1) :6289.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-50202R/

Reference Standards